The value of gonadotrophin releasing hormone analogue in an intrauterine insemination (IUI) programme.
Gonadotrophin releasing hormone analogue (GnRHa) is widely used in in-vitro fertilisation programmes and has no doubt led to a significant improvement in the pregnancy rate as well as cycle planning. However, its use in intrauterine insemination (IUI) programmes remains controversial. This is a retrospective review of patients who received IUI treatment at our assisted conception unit, during a 12-month period from August 1997 to July 1998. Fifty-two patients underwent a total of 85 cycles. Six cycles were abandoned, five due to excessive response and one for continuous bleeding. They all received Nafarelin nasal spray from day 2 until ovulatory HCG was administered. Metrodin injection was given from day 3. There were 18 clinical pregnancies. Seventy-nine cycles were completed giving a pregnancy rate of 22.8% per completed cycle. There were five (27.8%) multiple pregnancies. The use of GnRHa in our programme enabled us to achieve a good cycle control as well as flexibility in the timing of insemination such that weekend work was avoided. We conclude that the use of GnRHa facilitates the efficiency of an IUI programme.
Olagundoye
V O
VO
New Cross Hospital, Wolverhampton, UK.
Adeghe
J H
JH